Santa Monica, CA, 26 January 2017 – Trethera, a biotechnology company focused on the discovery and development of innovative small molecules for the treatment of hematological and solid tumors will be attending Sachs Associates 10th Annual European Life Sciences CEO Forum & Exhibition being held on 6th-7th March, 2017 at the Hilton Zurich Airport Hotel, Switzerland. […]
http://trethera.com/wp-content/uploads/2015/12/trethera_logo-wo.png00adminhttp://trethera.com/wp-content/uploads/2015/12/trethera_logo-wo.pngadmin2017-01-26 19:05:452017-03-06 14:02:57Sachs Associates 10 Annual European Life Sciences CEO Forum & Exhibition, 2017
25 January 2017 SCRIP Emerging Company Profile: University spinout, Trethera – which recently signed a licensing deal to develop Nanotherapeutics Inc.’s ribonucleotide reductase inhibitor Triapine – believes it is the first company to target cancer nucleotide metabolism through a combination approach. Read Article
Santa Monica, CA and Alachua, FL, January 5, 2017 – Trethera Corporation and Nanotherapeutics, Inc. today announced the signing of an exclusive worldwide agreement whereby Nanotherapeutics has granted Trethera an exclusive license for the global development, manufacturing and marketing of Triapine® (3-AP) and all formulations, for the treatment of hematological malignancies. Triapine® is a clinical-stage, […]
http://trethera.com/wp-content/uploads/2015/12/trethera_logo-wo.png00adminhttp://trethera.com/wp-content/uploads/2015/12/trethera_logo-wo.pngadmin2017-01-05 13:19:532017-01-05 13:20:23Trethera Corporation and Nanotherapeutics Sign Exclusive Worldwide Agreement for Rights to Triapine® in Hematological Malignancies
September 7, 2017 – Trethera, a biotechnology company developing innovative small molecule inhibitors of cancer nucleotide metabolism, will be attending the BioPharma America conference in Boston, MA, September 26-27, 2017.
http://trethera.com/wp-content/uploads/2015/12/trethera_logo-wo.png00Neil Bajpayeehttp://trethera.com/wp-content/uploads/2015/12/trethera_logo-wo.pngNeil Bajpayee2017-09-07 20:43:392017-09-07 20:43:39Trethera at BioPharm America
September 7, 2017 – Trethera, a biotechnology company developing innovative small molecule inhibitors of cancer nucleotide metabolism, will be attending RESI Boston 2017 on September 26, 2017.
http://trethera.com/wp-content/uploads/2015/12/trethera_logo-wo.png00Neil Bajpayeehttp://trethera.com/wp-content/uploads/2015/12/trethera_logo-wo.pngNeil Bajpayee2017-09-07 20:39:112017-09-07 20:39:11Trethera to attend RESI Boston 2017
Sachs Associates 10 Annual European Life Sciences CEO Forum & Exhibition, 2017
/in Events, News /by adminSanta Monica, CA, 26 January 2017 – Trethera, a biotechnology company focused on the discovery and development of innovative small molecules for the treatment of hematological and solid tumors will be attending Sachs Associates 10th Annual European Life Sciences CEO Forum & Exhibition being held on 6th-7th March, 2017 at the Hilton Zurich Airport Hotel, Switzerland. […]
UCLA Spinout Trethera Trials Novel DNA Metabolism Combination
/in In the News, News /by admin25 January 2017 SCRIP Emerging Company Profile: University spinout, Trethera – which recently signed a licensing deal to develop Nanotherapeutics Inc.’s ribonucleotide reductase inhibitor Triapine – believes it is the first company to target cancer nucleotide metabolism through a combination approach. Read Article
Trethera Corporation and Nanotherapeutics Sign Exclusive Worldwide Agreement for Rights to Triapine® in Hematological Malignancies
/in News /by adminSanta Monica, CA and Alachua, FL, January 5, 2017 – Trethera Corporation and Nanotherapeutics, Inc. today announced the signing of an exclusive worldwide agreement whereby Nanotherapeutics has granted Trethera an exclusive license for the global development, manufacturing and marketing of Triapine® (3-AP) and all formulations, for the treatment of hematological malignancies. Triapine® is a clinical-stage, […]